LUCA Biologics Revenue and Competitors
Estimated Revenue & Valuation
- LUCA Biologics's estimated annual revenue is currently $775k per year.
- LUCA Biologics's estimated revenue per employee is $155,000
Employee Data
- LUCA Biologics has 5 Employees.
- LUCA Biologics grew their employee count by 0% last year.
LUCA Biologics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | Chief Scientist | Reveal Email/Phone |
LUCA Biologics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is LUCA Biologics?
LUCA Biologics is a biotechnology company developing a new class of living medicines targeting the vaginal microbiome to impact reproductive and urogenital health. Emerging from the lab of Dr. Jacques Ravel, Primary Investigator on the vaginal microbiome division of the NIH's Human Microbiome Project, our platform takes a metagenomic and metatranscriptomic approach to the identification, screening and validation of strains with therapeutic potential. Our pipeline includes therapeutics for urinary tract infection (UTI), preterm birth (PTB), bacterial vaginosis (BV), and infertility. LUCA Biologics is a Seed Health foundry company.
keywords:N/AN/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.6M | 5 | -17% | N/A |
#2 | $0.4M | 5 | 25% | $52.5M |
#3 | $0.1M | 5 | 0% | $4.5M |
#4 | $0.8M | 5 | -17% | N/A |
#5 | $0.4M | 5 | -17% | N/A |